AR082366A1 - DERMOCORTICOID FORMULATION - Google Patents

DERMOCORTICOID FORMULATION

Info

Publication number
AR082366A1
AR082366A1 ARP110100832A ARP110100832A AR082366A1 AR 082366 A1 AR082366 A1 AR 082366A1 AR P110100832 A ARP110100832 A AR P110100832A AR P110100832 A ARP110100832 A AR P110100832A AR 082366 A1 AR082366 A1 AR 082366A1
Authority
AR
Argentina
Prior art keywords
composition according
weight
water
glycerol
corticosteroid
Prior art date
Application number
ARP110100832A
Other languages
Spanish (es)
Original Assignee
Fabre Pierre Dermo Cosmetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Pierre Dermo Cosmetique filed Critical Fabre Pierre Dermo Cosmetique
Publication of AR082366A1 publication Critical patent/AR082366A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición dermatológica que comprende un corticoide asociado con una base emoliente que consiste en una emulsión aceite en agua o agua en aceite de glicerol, vaselina y parafina líquida.Reivindicación 2: Composición de acuerdo con la reivindicación 1, que además comprende escualano. Reivindicación 5: Composición de acuerdo con una de las reivindicaciones precedentes, en la que el corticoide es dipropionato de betametasona. Reivindicación 17: Composición de acuerdo con una cualquiera de las reivindicaciones precedentes, que comprende: aproximadamente 0,005% a 0,1% en peso de corticoesteroide; aproximadamente 15% en peso de glicerol; aproximadamente 8% en peso de vaselina; aproximadamente 2% en peso de parafina líquida; y en calidad de excipientes: ácido esteárico, monoestearato de glicerol, decametilciclopentasiloxano, polietilenglicol 600, clorocresol, dimeticona, estearato de macrogol y agua. Reivindicación 19: Dispositivo transdérmico que comprende una composición de acuerdo con una cualquiera de las reivindicaciones 1 a 17 sobre el lado en contacto con la piel.A dermatological composition comprising a corticosteroid associated with an emollient base consisting of an oil-in-water or water-in-oil emulsion of glycerol, petrolatum and liquid paraffin. Claim 2: Composition according to claim 1, further comprising squalane. Claim 5: Composition according to one of the preceding claims, wherein the corticosteroid is betamethasone dipropionate. Claim 17: Composition according to any one of the preceding claims, comprising: about 0.005% to 0.1% by weight of corticosteroids; about 15% by weight glycerol; approximately 8% by weight petroleum jelly; approximately 2% by weight of liquid paraffin; and as excipients: stearic acid, glycerol monostearate, decamethylcyclopentasiloxane, polyethylene glycol 600, chlorocresol, dimethicone, macrogol stearate and water. Claim 19: Transdermal device comprising a composition according to any one of claims 1 to 17 on the side in contact with the skin.

ARP110100832A 2010-03-15 2011-03-15 DERMOCORTICOID FORMULATION AR082366A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1051836A FR2957260B1 (en) 2010-03-15 2010-03-15 NEW DERMOCORTICOID FORMULATION

Publications (1)

Publication Number Publication Date
AR082366A1 true AR082366A1 (en) 2012-12-05

Family

ID=42670368

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100832A AR082366A1 (en) 2010-03-15 2011-03-15 DERMOCORTICOID FORMULATION

Country Status (4)

Country Link
AR (1) AR082366A1 (en)
FR (1) FR2957260B1 (en)
TW (1) TW201138850A (en)
WO (1) WO2011113826A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928962A1 (en) * 2013-10-28 2015-05-07 Morten SLOTH WEIDNER Dermatological compositions
WO2016198472A1 (en) 2015-06-09 2016-12-15 Hpf Ip Holding S.A. Topical delivery system
FR3090385B1 (en) * 2018-12-21 2021-01-08 Pf Medicament Emollient composition in the form of an emulsion

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58162516A (en) * 1982-03-20 1983-09-27 Fujisawa Pharmaceut Co Ltd Steroid-containing water-in-oil type emulsion
US5635497A (en) 1982-06-23 1997-06-03 Yamanouchi Europe B.V. Topical application compositions
WO1993001836A1 (en) * 1991-07-16 1993-02-04 Schering Aktiengesellschaft Berlin Und Bergkamen Method of producing semi-solid preparations containing micro-particulate substances
US8449867B2 (en) * 2004-08-31 2013-05-28 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions
CA2632616A1 (en) 2005-12-09 2007-06-21 Nycomed Us Inc. Topical glucocorticosteroid formulations
US8200084B2 (en) 2007-11-01 2012-06-12 Futurewei Technologies, Inc. Encoding for information needed for routing and wavelength assignment in wavelength switched optical networks
FR2931073B1 (en) * 2008-05-16 2010-08-20 Fabre Pierre Dermo Cosmetique EMOLLIENT COMPOSITION

Also Published As

Publication number Publication date
TW201138850A (en) 2011-11-16
WO2011113826A1 (en) 2011-09-22
FR2957260A1 (en) 2011-09-16
FR2957260B1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
BR112015019657A2 (en) topical compositions and methods of use thereof
PE20120584A1 (en) TRANSDERMAL PHARMACEUTICAL PREPARATIONS
CO6640250A2 (en) Topical formulation comprising (r) -3-cyclopentyl-3- (4- (7h-pyrrolo (2,3-d) pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile or a pharmaceutically acceptable salt of same and an oil-in-water emulsion
CL2007002095A1 (en) Topical pharmaceutical composition comprising 1- (2-methylpropyl) -1h-imidazo [4,5-c] quinolin-4-amine; packaged composition; method to sterilize it; Useful to heal tissue where the dermis has torn.
MX2020002881A (en) Compositions and methods for topical delivery of prostaglandins to subcutaneous fat.
EA201291108A1 (en) PHARMACEUTICAL COMPOSITIONS IN THE FORM OF EMULSION WITH LOW CONTENT OF OIL, CONTAINING PROGESTOGEN
BR112012010083B8 (en) Sustained-release topical pharmaceutical composition and related use
ITMI20130555A1 (en) PHARMACEUTICAL OR COSMETIC COMPOSITION TO COUNTER SKIN AGING THROUGH AN ANTI-INFLAMMATORY ACTION
BR112012017554B8 (en) solid-forming local anesthetic formulations for pain control
CL2011002755A1 (en) Topical pharmaceutical composition comprising nanoporous, spherical calcium phosphate particles, where at least 90% or more of the particles have an average diameter of 2 microns or less and are bound to a pharmacologically active agent.
CO6640244A2 (en) Topical pharmaceutical compositions
HRP20230726T1 (en) Topical formulation for promoting wound healing
AR055591A1 (en) A SKIN PROTECTIVE TOPIC COMPOSITION AND ITS USE
AU2014349256A1 (en) Sprayable topical carrier and composition comprising phosphatidylcholine
AR091039A1 (en) TOPIC PHARMACEUTICAL COMPOSITIONS THAT INCLUDE TERBINAFINE, USE AND TREATMENT METHOD
HRP20211817T1 (en) Method of adjuvant cancer treatment
AR065317A1 (en) USE OF CHITOSANS, DERIVATIVES OF CHITOSANS AND A PHYSIOLOGICALLY ACCEPTABLE SALT OF THE SAME FOR THE TREATMENT OF UNGUE INFLAMMATORY DISEASES
AR092840A1 (en) DEGARELIX ELABORATION
PH12018500910A1 (en) Novel method of use and compositions
AR082366A1 (en) DERMOCORTICOID FORMULATION
BR112015027436A8 (en) topical composition and vehicle for administration of pharmaceutically or cosmetically active ingredients
CO2022002253A2 (en) topical compositions
BR112015001627A2 (en) pharmaceutical composition, their uses and method of decreasing the frequency of urination
ES2676701T3 (en) Topical aqueous gel-type compositions in the form of a homogeneous suspension of an active substance in the class of retinoids containing at least one hydrophobic silica
RU2016117298A (en) Acitretin Topical Pharmaceutical Compositions

Legal Events

Date Code Title Description
FB Suspension of granting procedure